Drug · DIN 02347172
VYVANSE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since June 24, 2021; first marketed April 14, 2010.
- Drug Identification Number (DIN)
- 02347172
- Company (DIN owner)
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Schedule
- Controlled drugs (CDSA I)
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Lisdexamfetamine N06BA12
- Class
- Human
- Record last updated
- October 16, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LISDEXAMFETAMINE DIMESYLATE | 60 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 23, 2020: NOC 23943New Drug Submission (NDS) · Administrative: Merger/Buy-out
- March 16, 2015: NOC 16693New Drug Submission (NDS) · Manufacturer name change
- March 19, 2010: NOC 11160Supplement to a New Drug Submission (SNDS) · New strengths: 20 mg, 40 mg and 60 mg
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “vyvanse”. A notice may cover another product or only some lots: read it to see what it covers.
- Vyvanse Capsule (2019-08-08)August 8, 2019 · Drugs · Product safety · Type III
- Vyvanse (2015-12-23)December 31, 2015 · Drugs · Product safety · Type III
Other DINs named VYVANSE
- DIN 02322951 · Marketed
- DIN 02322978 · Marketed
- DIN 02347156 · Marketed
- DIN 02347164 · Marketed
- DIN 02439603 · Marketed
- DIN 02458071 · Marketed
- DIN 02490226 · Marketed
- DIN 02490234 · Marketed
- DIN 02490242 · Marketed
- DIN 02490250 · Marketed
- DIN 02490269 · Marketed
- DIN 02490277 · Marketed